BTOG 2019 | mLIPI as a predictor of nivolumab outcomes in advanced NSCLC

Kenneth O'Byrne

Ken O’Byrne, MD, of the Princess Alexandra Hospital, Brisbane, Queensland, Australia, discusses the use of the modified Lung Immune Predictive Index (mLIPI) as a predictive tool of nivolumab outcomes and immune-related adverse events in advanced non-small cell lung cancer (NSCLC). Speaking from the British Thoracic Oncology Group (BTOG) 2019 Annual Conference in Dublin, Ireland, Prof. O’Byrne also discusses the benefits of combining this measure with PD-L1 expression testing.

Share this video